Clinical Trials on Advanced or Metastatic NRAS-mutant Melanoma in Singapore
Total 21 results
-
Novartis PharmaceuticalsRecruitingAdvanced EGFRmutant NonSmallSellLungCancer (NSCLC),KRAS G12-mutant NSCLC,Esophageal SquamousCellCancer (SCC),Head/Neck SCC,MelanomaNetherlands, Korea, Republic of, Spain, Taiwan, Japan, Italy, United States, Singapore, Canada
-
BayerCompletedAdvanced or Metastatic Solid TumorUnited States, Spain, Korea, Republic of, Belgium, Singapore, Germany
-
Taiho Oncology, Inc.Active, not recruitingAdvanced or Metastatic Solid Tumor | Advanced or Metastatic Gastric or Gastroesophageal Cancer | Myeloid or Lymphoid Neoplasms (MLN)United States, Spain, Turkey, Hong Kong, Korea, Republic of, Belgium, Japan, Netherlands, France, Germany, Italy, Sweden, United Kingdom, Portugal, Singapore
-
AstraZenecaCompletedAdvanced or Metastatic Breast Cancer | ER+ve Advanced or Metastatic Breast CancerCanada, France, Korea, Republic of, Czechia, Peru, United Kingdom, Spain, Japan, Mexico, Singapore, Bulgaria
-
Gilead SciencesEverest MedicinesActive, not recruitingLocally Advanced or Metastatic Unresectable Urothelial CancerUnited States, Belgium, France, Spain, United Kingdom, Korea, Republic of, Czechia, Germany, Israel, China, Italy, Australia, Hong Kong, Taiwan, Portugal, Singapore, Croatia, Greece, Turkey, Sweden, Switzerland, Canada, Austria, Bulgaria and more
-
HUYABIO International, LLC.Bristol-Myers SquibbRecruitingUnresectable or Metastatic Melanoma | Progressive Brain MetastasisSpain, United States, Italy, Japan, Belgium, France, New Zealand, Brazil, Korea, Republic of, Australia, Germany, Singapore, Czechia, Austria, South Africa, United Kingdom, Puerto Rico
-
BayerRecruitingLocally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene FusionUnited States, Austria, Denmark, Germany, Italy, Norway, Spain, United Kingdom, Brazil, Russian Federation, Switzerland, Taiwan, Canada, China, Australia, Greece, Belgium, Sweden, Korea, Republic of, France, Argentina, Finland, Ireland and more
-
Novartis PharmaceuticalsTerminatedAdvanced or Metastatic ER+ Breast CancerUnited States, France, Germany, Singapore, Italy, Japan, Belgium
-
Novartis PharmaceuticalsRecruitingLocally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutationItaly, Spain, United States, France, Thailand, Malaysia, China, Germany, India, Turkey, Belgium, Argentina, Bulgaria, Netherlands, Hungary, Greece, Portugal, Austria, Singapore, Brazil, United Kingdom
-
Bristol-Myers SquibbCompletedLocally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal JunctionFrance, Poland, Russian Federation, Taiwan, United States, Hong Kong, Spain, Germany, Italy, Japan, Korea, Republic of, Singapore
-
Hummingbird BioscienceMerck KGaA, Darmstadt, GermanyRecruitingAdvanced or Metastatic Squamous Non-Small Cell Lung CancerAustralia, Singapore
-
AstraZenecaDaiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, TokyoActive, not recruitingAdvanced or Metastatic Breast CancerUnited States, Belgium, Canada, Denmark, France, Italy, Spain, Hungary, Poland, Taiwan, Russian Federation, Germany, Korea, Republic of, Brazil, Japan, Mexico, United Kingdom, China, Israel, Austria, Australia, Saudi Arabia, Netherl... and more
-
Hoffmann-La RocheActive, not recruitingEstrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast CancerUnited States, Korea, Republic of, China, Poland, Taiwan, Turkey, United Kingdom, Australia, Argentina, Germany, Singapore, Thailand, Israel, Russian Federation, Ukraine, Brazil, South Africa
-
Novartis PharmaceuticalsRecruitingMSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal CancersJapan, Italy, Spain, Singapore, Belgium, Germany, Korea, Republic of, Taiwan, France, Israel, Norway, United States
-
Gilead SciencesRecruitingStage IV Breast Cancer | Locally Advanced or Unresectable Metastatic Breast CancerTaiwan, Korea, Republic of, Greece, Spain, United States, Israel, France, Japan, Belgium, Poland, China, Singapore, Australia, Hungary, Czechia, Italy, South Africa, Hong Kong, Chile, Brazil, Argentina, Austria, Canada, Germany, Portugal, United Kingdom
-
Genentech, Inc.RecruitingEstrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast CancerKorea, Republic of, United States, Spain, Taiwan, United Kingdom, Japan, Germany, Argentina, Turkey, Greece, Italy, Singapore, South Africa
-
AbbVie (prior sponsor, Abbott)Genentech, Inc.CompletedAdvanced or Metastatic Non-Small Cell Lung CancerUnited States, Australia, Brazil, Czech Republic, Russian Federation, Singapore
-
AstraZenecaDaiichi SankyoRecruitingLocally Advanced or Metastatic Non-Small Cell Lung CancerKorea, Republic of, Italy, Poland, Malaysia, Taiwan, Thailand, United States, France, Netherlands, Philippines, Canada, Singapore, Spain, Turkey, Australia, Belgium, Israel
-
Taiho Oncology, Inc.RecruitingAdvanced or Metastatic NSCLS With Exon 20 Insertion MutationUnited States, Spain, Canada, Italy, Israel, Japan, United Kingdom, Korea, Republic of, Germany, France, Turkey, Belgium, Netherlands, Philippines, Poland, Singapore
-
AstraZenecaActive, not recruitingCervical Cancer | Ovarian Cancer | Pharmacokinetics | Endometrial Cancer | Pharmacodynamics | Safety and Tolerability | Advanced Solid Malignancy | Tumour Response | Advanced or Metastatic Breast Cancer | PIK3CA | AKT1 | PTEN | ER Positive | HER2 PositiveUnited States, Italy, Canada, France, Japan, United Kingdom, Spain, Netherlands, Denmark, Singapore
-
Hoffmann-La RocheActive, not recruitingAdvanced or Metastatic Esophageal Squamous Cell CarcinomaKorea, Republic of, Argentina, Denmark, France, Spain, Brazil, United Kingdom, Turkey, Czechia, Thailand, Russian Federation, Italy, Poland, Taiwan, Singapore, Ukraine, Kenya, Hungary